Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial
| Autor: | S G Arbuck, Robert J. Mayer, R Gonin, James A. DeCaprio |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty medicine.medical_treatment Leucovorin Adenocarcinoma Gastroenterology Drug Administration Schedule Internal medicine Pancreatic cancer Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Aged 80 and over Chemotherapy business.industry Middle Aged medicine.disease Survival Analysis Confidence interval Surgery Pancreatic Neoplasms Diarrhea medicine.anatomical_structure Oncology Fluorouracil Toxicity Drug Evaluation Female medicine.symptom Pancreas business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 9:2128-2133 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.1991.9.12.2128 |
| Popis: | Forty-two previously untreated patients with advanced, measurable adenocarcinoma of the pancreas were treated with weekly fluorouracil (5-FU; 600 mg/m2 intravenous [IV]) and leucovorin 500 mg/m2 IV for 6 weeks followed by a 2-week rest. A median of 11 (range, one to 76) doses were given. There were three partial responses (three of 42 [7%]; exact 95% confidence interval, 1% to 19%) and no complete responses. Median survival was 6.2 months, with seven patients surviving longer than 12 months. The most common toxicity was diarrhea; there was one treatment-related death. Despite promising results in patients with advanced colorectal cancer, this dose schedule of 5-FU and leucovorin does not appear to be superior to 5-FU alone for the treatment of advanced pancreatic cancer. Alternative investigative approaches are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|